Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Capital Expenditures (2016 - 2024)

Karyopharm Therapeutics (KPTI) has disclosed Capital Expenditures for 11 consecutive years, with -$53000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures changed N/A year-over-year to -$53000.0, compared with a TTM value of -$53000.0 through Sep 2025, down 127.18%, and an annual FY2024 reading of $142000.0, changed N/A over the prior year.
  • Capital Expenditures was -$53000.0 for Q4 2024 at Karyopharm Therapeutics, down from $195000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $207000.0 in Q4 2021 and bottomed at -$53000.0 in Q4 2024.
  • Average Capital Expenditures over 4 years is $68555.6, with a median of $39000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures tumbled 79.59% in 2020, then skyrocketed 680.0% in 2022.
  • Year by year, Capital Expenditures stood at $119000.0 in 2020, then surged by 73.95% to $207000.0 in 2021, then tumbled by 81.16% to $39000.0 in 2022, then plummeted by 235.9% to -$53000.0 in 2024.
  • Business Quant data shows Capital Expenditures for KPTI at -$53000.0 in Q4 2024, $195000.0 in Q1 2024, and $39000.0 in Q3 2022.